Roche Molecular Systems, Inc.

The Scripps Research Institute

Roche Diagnostics Gmbh

F. Hoffmann-La Roche Ag

Alison Tsan

Amar Gupta

Randall K Saiki

Igor Kozlov

Stephen Gordon Will

Nicolas Newton

Nancy J Schoenbrunner

Randall Saiki

Stephen G Will

Dieter Heindl

Henry A Erlich

Veeraiah Bodepudi

Daniel R Salomon

Wei-min Liu

Stefanie Froehner

Cherie Holcomb

Dirk Kessler

Xiaoju Max Ma

Chitra Manohar

Lori Steiner

Nick Newton

Bryan Hoglund

Melinda Rastrou

Priscilla Moonsamy

Nikolaus-Peter Stengele

Volker Gatterdam

Wei-Min Liu

Nancy Schoenbrunner

The present invention describes methods for performing higher multiplexed real-time PCR for detection and quantitation of target nucleic acids using tagged hydrolysis probes.

Methods for performing multiplexed real-time PCR

The present invention describes methods for performing higher multiplexed PCR for detection and quantitation of target nucleic acids using tagged hydrolysis probes.

Methods for performing multiplexed PCR

The present invention describes methods for performing higher multiplexed real-time PCR for detection and quantitation of target nucleic acids using TAGS hydrolysis probes.

Methods for performing multiplexed real-time PCR in a self-contained nucleic acid analysis pouch

The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.

Methods and compositions for detecting mutation in the human EZH2 gene

The invention is a method of detecting or assessing solid organ graft (transplant) rejection by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient. The invention further comprises a method of detecting the presence of maternal cells in a blood sample of an offspring.

Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems

Six new mutations were found in exon 19 of the EGFR gene, the exon that is often mutated in tumors. The invention comprises methods of detecting the mutations, methods of prognosis and methods of predicting response to treatment based on the presence of absence of the mutations.

Complex mutations in the epidermal growth factor receptor kinase domain

The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3'-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, wherein the allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has said complementary 3&#x2032;-terminal nucleotide.

Allele-specific amplification

The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having at least one selective nucleotide complementary to only one variant of the target sequence and incorporating at least one 'G-clamp' nucleotide.

Use of G-clamp for improved allele-specific PCR

The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having at least one selective nucleotide complementary to only one variant of the target sequence and incorporating both a nucleotide with a base covalently modified at the exocyclic amino group and a modified phosphate.

Primers with modified phosphate and base in allele-specific PCR

The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, having an internally-placed selective nucleotide complementary to only one variant of the target sequence wherein the allele-specific oligonucleotide is extended by a nucleic acid polymerase predominantly or exclusively when hybridized to the variant of the target sequence for which it has said complementary selective nucleotide.

Allele-specific amplification of nucleic acids

The present invention relates to a method, oligonucleotides, reaction mixtures and kits for the selective amplification of a messenger RNA target comprising an exon-exon junction, using an oligonucleotide that comprises at least one nucleotide modified at the exocyclic amino group.

Growing community of inventors

Danville, CA, United States of America

Alison Tsan